102 related articles for article (PubMed ID: 28952222)
21. Tumor-Derived Exosomal Long Noncoding RNAs as Promising Diagnostic Biomarkers for Prostate Cancer.
Wang YH; Ji J; Wang BC; Chen H; Yang ZH; Wang K; Luo CL; Zhang WW; Wang FB; Zhang XL
Cell Physiol Biochem; 2018; 46(2):532-545. PubMed ID: 29614511
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers.
Weng J; Wang J; Cai Y; Stafford LJ; Mitchell D; Ittmann M; Liu M
Int J Cancer; 2005 Feb; 113(5):811-8. PubMed ID: 15499628
[TBL] [Abstract][Full Text] [Related]
23. Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate.
Gelmini S; Tricarico C; Petrone L; Forti G; Amorosi A; Dedola GL; Serio M; Pazzagli M; Orlando C
Clin Chem Lab Med; 2003 Mar; 41(3):261-5. PubMed ID: 12705330
[TBL] [Abstract][Full Text] [Related]
24. Detection of pim-1 mRNA in prostate cancer diagnosis.
He HC; Bi XC; Dai QS; Wang SS; Wei HA; Zhong WD; Liu WH; Jiang FN; Liu LS
Chin Med J (Engl); 2007 Sep; 120(17):1491-3. PubMed ID: 17908456
[TBL] [Abstract][Full Text] [Related]
25. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer.
Li R; Erdamar S; Dai H; Wheeler TM; Frolov A; Scardino PT; Thompson TC; Ayala GE
Hum Pathol; 2007 Oct; 38(10):1501-7. PubMed ID: 17597184
[TBL] [Abstract][Full Text] [Related]
26. Expression, localisation and potential significance of aquaporins in benign and malignant human prostate tissue.
Bründl J; Wallinger S; Breyer J; Weber F; Evert M; Georgopoulos NT; Rosenhammer B; Burger M; Otto W; Rubenwolf P
BMC Urol; 2018 Sep; 18(1):75. PubMed ID: 30176851
[TBL] [Abstract][Full Text] [Related]
27. Differential RNA expression of the pS2 gene in the human benign and malignant prostatic tissue.
Colombel M; Dante R; Bouvier R; Ribieras S; Pangaud C; Marechal JM; Lasne Y
J Urol; 1999 Sep; 162(3 Pt 1):927-30. PubMed ID: 10458410
[TBL] [Abstract][Full Text] [Related]
28. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
Schmittgen TD; Teske S; Vessella RL; True LD; Zakrajsek BA
Int J Cancer; 2003 Nov; 107(2):323-9. PubMed ID: 12949815
[TBL] [Abstract][Full Text] [Related]
29. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
[TBL] [Abstract][Full Text] [Related]
31. Expression of c-MET/HGF receptor mRNA and protein in human non-malignant and malignant prostate tissues.
Tsuka H; Mori H; Li B; Kanamaru H; Matsukawa S; Okada K
Int J Oncol; 1998 Nov; 13(5):927-34. PubMed ID: 9772281
[TBL] [Abstract][Full Text] [Related]
32. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
34. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
35. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
36. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
37. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
38. [Correlation of FOXA1 with the malignancy and progression of prostate cancer].
Feng W; Zhang HB; Wang YM; Hu JL
Zhonghua Nan Ke Xue; 2015 May; 21(5):414-9. PubMed ID: 26117938
[TBL] [Abstract][Full Text] [Related]
39. Developing a model for forecasting Gleason score ≥7 in potential prostate cancer patients to reduce unnecessary prostate biopsies.
Li X; Pan Y; Huang Y; Wang J; Zhang C; Wu J; Cheng G; Qin C; Hua L; Wang Z
Int Urol Nephrol; 2016 Apr; 48(4):535-40. PubMed ID: 26810323
[TBL] [Abstract][Full Text] [Related]
40. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]